ライフサイエンスコーパス: gentamicin

1 reams but containing neither paromomycin nor gentamicin).

2 infusion (BHI) agar with chloramphenicol and gentamicin.

3 not affect the activity of ciprofloxacin and gentamicin.

4 ylprednisolone reduces vertigo compared with gentamicin.

5 sponders switched from methylprednisolone to gentamicin.

6 ctors, or the presence of the aminoglycoside gentamicin.

7 uction of ROS and apoptotic cells induced by gentamicin.

8 tion of injectable procaine benzylpenicillin-gentamicin.

9 ciprofloxacin, tobramycin, tetracycline, and gentamicin.

10 4-oxadiazol-3-yl]benzoic acid (ataluren) and gentamicin.

11 o susceptibility to other antibiotics except gentamicin.

12 egalin and investigated its interaction with gentamicin.

13 G, amoxicillin, doxycycline, rifampicin and gentamicin.

14 became susceptible to cell death induced by gentamicin.

15 oprim-sulfamethoxazole, chloramphenicol, and gentamicin.

16 s were protected from degeneration caused by gentamicin.

17 l describing the complex between megalin and gentamicin.

18 development of synergistic combinations with gentamicin.

19 cells protected from bactericidal effects of gentamicin.

20 eloped, each validated using the nephrotoxin gentamicin.

21 rom a 12-month controlled trial of nebulized gentamicin.

22 o amoxicillin, cefotaxime, tetracycline, and gentamicin.

23 d 292 (82%) of 358 participants allocated to gentamicin.

24 hat of commercial antibiotics ampicillin and gentamicin.

25 -malaria drug chloroquine and the antibiotic gentamicin.

26 ch is comparable with that of ampicillin and gentamicin.

27 ine alone or doxycycline in combination with gentamicin.

28 ) to produce G418 during the biosynthesis of gentamicins.

29 6.56), cefpodoxime (1.91; 95%CI: 0.46-3.36), gentamicin (0.89; 95%CI: 0.06-1.84) and ciprofloxacin (0

30 Of 648 patients enrolled, 245 received gentamicin (222 of 309 [72%] in hospital A and 23 of 339

31 eceive a single intramuscular dose of either gentamicin 240 mg (gentamicin group) or ceftriaxone 500

32 l gonorrhea were randomly assigned to either gentamicin 240 mg intramuscularly plus azithromycin 2 g

33 with the CDC's current alternative regimen (gentamicin 240 mg plus azithromycin 2 g) given increases

34 Thus, we did not find that a single dose of gentamicin 240 mg was non-inferior to a single dose of c

35 rhea with CDC's current alternative regimen (gentamicin 240mg plus azithromycin 2g) given increases i

36 eA (for erythromycin; 27.41%), aac-3-IV (for gentamicin; 25.38%), and the two genes cmlA (24.87%) and

37 to ciprofloxacin (59%), cefepime (35%), and gentamicin (38%).

38 oxacillin (two doses of 1 g) and single-dose gentamicin (4 mg/kg) was associated with a 94% increase

39 atympanic methylprednisolone (62.5 mg/mL) or gentamicin (40 mg/mL) injections given 2 weeks apart, an

40 significantly higher rates of resistance to gentamicin (43%), trimethoprim-sulphamethoxazole (60%),

41 ial isolates to ciprofloxacin (11.1%-24.2%), gentamicin (5.6-31.0%), tobramycin (17.2% -25.3%) and va

42 G418 was more effective than gentamicin (~50% rescue versus <10%), and the effect was

43 0%; ciprofloxacin, 95.0%; tobramycin, 90.6%; gentamicin, 80.6%; and sulfamethoxazole/trimethoprim, 59

44 e treatment of procaine benzylpenicillin and gentamicin, 816 (751 per protocol) were allocated amoxic

45 nce interval [CI], 73 to 87) for paromomycin-gentamicin, 82% (95% CI, 74 to 87) for paromomycin alone

46 lities were the following: vancomycin, 100%; gentamicin, 88.0%; sulfamethoxazole/trimethoprim, 77.5%;

47 Overall susceptibility was highest for gentamicin (94%), which was also true of the CNS isolate

48 We implement NRS to detect gentamicin, a commonly IV-administered antibiotic and EC

49 umin was markedly reduced in the presence of gentamicin, a competitive inhibitor of megalin-dependent

50 Pharmaceutical gentamicin, a mixture of several related aminoglycosides

51 sistive microcantilever sensor for detecting gentamicin, a peritonitis therapeutic small-molecule dru

52 l antibiotic protocols recommended empirical gentamicin add-on therapy in only 1 of the units.

53 Both topical and intradermal gentamicin administration induced type VII collagen and

54 we determined whether topical or intradermal gentamicin administration induces type VII collagen and

55 in plus ceftriaxone (AC) and ampicillin plus gentamicin (AG) combinations for treating Enterococcus f

56 we studied the combination of L-arginine and gentamicin against planktonic persisters through time-ki

57 Gentamicin alone failed to eradicate N. gonorrhoeae from

58 Gentamicin alone failed to eradicate Neisseria gonorrhoe

59 The efficacy of gentamicin alone in the treatment of pharyngeal gonorrhe

60 rin], ciprofloxacin [a fluoroquinolone], and gentamicin [an aminoglycoside]).

61 ated sp(3) carbon during the biosynthesis of gentamicin, an aminoglycoside antibiotic.

62 receive injectable procaine benzylpenicillin-gentamicin and 1163 infants to receive oral amoxicillin.

63 m were enrolled and randomly assigned: 30 to gentamicin and 30 to methylprednisolone.

64 d Nov 14, 2016, and randomly assigned 358 to gentamicin and 362 to ceftriaxone.

65 containing the non-cell-permeant antibiotic gentamicin and a fluorescent marker.

66 e have also shown how the read-through drugs gentamicin and ataluren (PTC124) increase CLN1 (PPT1) en

67 Addition of vancomycin, gentamicin and fluconazol into ERC contrast media was ev

68 Compelling evidence is now available that gentamicin and Geneticin (G418) can induce the mammalian

69 Surprisingly, binding of gentamicin and kanamycin A to the chemically synthesized

70 days (group A, reference group); injectable gentamicin and oral amoxicillin for 7 days (group B); in

71 ides evidence of the efficacy of paromomycin-gentamicin and paromomycin alone for ulcerative L. major

72 examined the effect of 2 of these compounds, gentamicin and PTC124, in human-induced pluripotent stem

73 rature exposure on Candida growth in optisol-gentamicin and streptomycin (GS) with and without antifu

74 of all isolates had high-level resistance to gentamicin and streptomycin, respectively, including 10%

75 rate spatial control of release of entrapped gentamicin and temporal control of release of entrapped

76 ne is up-regulated following the addition of gentamicin and that this up-regulation is due to repress

77 ne conditions, we studied the combination of gentamicin and the clinically compatible basic amino aci

78 We demonstrated that a combination of gentamicin and the clinically compatible basic amino aci

79 illium notatum when compared with standards, gentamicin and tioconazole for bacteria and fungi, respe

80 ceived a single 360-mg intramuscular dose of gentamicin and underwent test of cure by culture 4-7 day

81 ed a single 360mg intramuscular (IM) dose of gentamicin and underwent test-of-cure (TOC) by culture 4

82 ve antimicrobial treatment with ticarcillin, gentamicin and vancomycin or levofloxacin eye drops lead

83 with the nonsense mutation suppressing drug gentamicin and we were able to induce expression of full

84 ) patients received ampicillin with low-dose gentamicin, and 150 (48%) patients received ampicillin m

85 per protocol) were allocated amoxicillin and gentamicin, and 817 (753 per protocol) were assigned pro

86 hose treated with procaine benzylpenicillin, gentamicin, and amoxicillin (risk difference with refere

87 ol) were assigned procaine benzylpenicillin, gentamicin, and amoxicillin.

88 have varying mechanisms of action-meropenem, gentamicin, and ceftazidime-highlighting the versatility

89 cin, clarithromycin, azithromycin, rifampin, gentamicin, and doxycycline against 101 isolates of Rhod

90 e to a range of drugs, including vancomycin, gentamicin, and mupirocin.

91 2, first-line injectable agents (ampicillin, gentamicin, and penicillin) had low variable availabilit

92 complex with paromomycin, geneticin (G418), gentamicin, and TC007, solved at 3.3- to 3.7-A resolutio

93 Resistance to fluoroquinolones, gentamicin, and tobramycin was seen in 1 patient each, r

94 is associated with resistance to ampicillin, gentamicin, and trimethoprim-sulfamethoxazole and with s

95 ic resistance to ciprofloxacin, clindamycin, gentamicin, and trimethoprim-sulfamethoxazole.

96 as treated with doxycycline, rifampicin, and gentamicin, and underwent surgical repair of a penetrati

97 ed, and bacteremia resolved with daptomycin, gentamicin, and/or linezolid treatment.

98 ght for the future structure-based design of gentamicin antagonists.

99 his study was to assess the effectiveness of gentamicin as an alternative to ceftriaxone (both combin

100 Efficacy of gentamicin as antibiotic lock treatment (ALT) at 5 mg/mL

101 Gentamicin/azithromycin and gemifloxacin/azithromycin we

102 Gentamicin/azithromycin cured 10 of 10 pharyngeal infect

103 .5%) of 202 evaluable participants receiving gentamicin/azithromycin, and 99.5% (lower 1-sided exact

104 readthrough activity but the minor component gentamicin B1 (B1) is a potent readthrough inducer.

105 Binding to megalin is highly similar to gentamicin binding to calreticulin.

106 Gentamicin binds to megalin with low affinity and exploi

107 g axis mediated hair cell protection against gentamicin by adjudin, at least in part.

108 Hospital gentamicin is a mixture of five gentamicin C-subtypes and several impurities of various

109 nts, with gentamicin C2b being the least and gentamicin C2 the most ototoxic.

110 es of ototoxicity in cochlear explants, with gentamicin C2b being the least and gentamicin C2 the mos

111 eive a cream containing 15% paromomycin-0.5% gentamicin (called WR 279,396), 15% paromomycin alone, o

112 sue culture and in mice, we demonstrate that gentamicin can induce expression and MHC class I present

113 Large doses of gentamicin cause nephrotoxicity and ototoxicity, enterin

114 thin a few minutes to different antibiotics, gentamicin, ceftazidime, nitrofurantoin, nalidixic acid,

115 -line antimicrobials (ampicillin/penicillin, gentamicin, ceftriaxone) among children <=5 years increa

116 efficacy studies, human-equivalent doses of gentamicin, ciprofloxacin, levofloxacin, and doxycycline

117 h in combination with low-dose, short-course gentamicin (clinical success rate, 44.2% [53/120] vs 41.

118 Efficacy was not associated with gentamicin Cmax or MIC.

119 ect to oral gavage with high dose kanamycin, gentamicin, colistin, metronidazole, vancomycin, individ

120 al significant difference in SSI between the gentamicin-collagen group (16 of 329 patients [4.9%]) an

121 degradable drug carrier systems, such as the gentamicin-collagen implant, is a potential avenue for S

122 Gentamicin-collagen implants decrease the rate of SSI.

123 Gentamicin-collagen implants have been previously assess

124 vant RCTs was conducted to determine whether gentamicin-collagen implants reduce SSI.

125 Gentamicin-collagen implants significantly reduced SSI [

126 Locally administered gentamicin-collagen sponges did not reduce the incidence

127 s as an injectable procaine benzylpenicillin-gentamicin combination for 7 days for situations in whic

128 ured creatinine at enrollment and TOC, serum gentamicin concentration post-dose to establish peak con

129 tinine at enrollment and test of cure, serum gentamicin concentration postdose to establish peak conc

130 and predict the health outcomes for varying Gentamicin concentrations.

131 cochlear explants, we found rapid uptake of gentamicin-conjugated Texas Red (GTTR) into hair cells f

132 of activity seen with commercially available gentamicin-containing cement control; whilst in vitro ge

133 Gentamicin-containing collagen sponges are widely used f

134 prophylaxis alone or with the addition of 2 gentamicin-containing collagen sponges into the hip join

135 Topical gentamicin corrected dermal-epidermal separation, improv

136 ule drug, protected cochlear hair cells from gentamicin damage.

137 In gentamicin-damaged BP, supporting cells expanded to fill

138 s confirmed that the GJIC remained robust in gentamicin-damaged explants, but regionally asymmetric c

139 gh correlation was expressed between them in gentamicin detection.

140 nsor can detect the small-molecule (< 2 kDa) gentamicin directly.

141 First, we demonstrated that gentamicin enhanced readthrough activity in cells transf

142 xicillin for 5 days (group C); or injectable gentamicin for 2 days and oral amoxicillin for 7 days (g

143 oup B); injectable procaine benzylpenicillin-gentamicin for 2 days, then oral amoxicillin for 5 days

144 receive injectable procaine benzylpenicillin-gentamicin for 7 days (group A, reference group); inject

145 tive as injectable procaine benzylpenicillin-gentamicin for 7 days on an outpatient basis in young in

146 atients treated before January 2007 received gentamicin for a significantly longer period (28 versus

147 ibiotic found to lose efficacy over time was gentamicin for gram-positive organisms (P = .005).

148 ndicate the therapeutic potential of topical gentamicin for NPPK.

149 efficacy at subtoxic doses limit the use of gentamicin for suppression therapy.

150 ish hospitals changed from cephalosporins to gentamicin for surgical antibiotic prophylaxis.

151 Low-dose gentamicin for the treatment of uncomplicated enterococc

152 nty exists regarding the role of synergistic gentamicin for uncomplicated Enterococcus faecalis bacte

153 ining 15% paromomycin, with and without 0.5% gentamicin, for cutaneous leishmaniasis caused by Leishm

154 ial source for endocytic protein uptake, and gentamicin further increased this concentration.

155 ne, ciprofloxacin, vancomycin, trimethoprim, gentamicin, fusidic acid, rifampin, and mupirocin) perfo

156 atment is not feasible include intramuscular gentamicin (GEN) and oral amoxicillin.

157 osa wild-type PAO1 and first-line antibiotic gentamicin (GEN) are used in our experiments.

158 To evaluate this effect, we tested gentamicin (GENT) in the inner ear following CGP deliver

159 PEGylated (2 KDa) lipids were modified with gentamicin (GM), a substrate to megalin receptors as we

160 g loss induced by aminoglycosides, including gentamicin (GM).

161 ased from 19.9 (SD 16.7) to 2.5 (5.8) in the gentamicin group (87% reduction) and from 16.4 (12.5) to

162 ed with 267 (91%) of 292 participants in the gentamicin group (adjusted risk difference -6.4%, 95% CI

163 in the injectable procaine benzylpenicillin-gentamicin group and 1145 (98%) infants in the oral amox

164 eported one adverse event each: three in the gentamicin group and three in the methylprednisolone gro

165 which was experienced by one patient in the gentamicin group and two in the methylprednisolone group

166 eftriaxone group and 163 (94%) of 174 in the gentamicin group had clearance at follow-up (adjusted ri

167 by a masked clinician (eight patients in the gentamicin group vs 15 in the methylprednisolone group).

168 visual analogue pain score 36 of 100 in the gentamicin group vs 21 of 100 in the ceftriaxone group).

169 ramuscular dose of either gentamicin 240 mg (gentamicin group) or ceftriaxone 500 mg (ceftriaxone gro

170 In the procaine benzylpenicillin-gentamicin group, 234 infants (22%) failed treatment, co

171 triaxone group compared with 82 [80%] in the gentamicin group; adjusted risk difference -15.3%, -24.0

172 riaxone group compared with 107 [90%] in the gentamicin group; adjusted risk difference -7.8%, -13.6

173 Children receiving low-dose gentamicin had approximately twice the risk of developin

174 atients who developed AKI after prophylactic gentamicin had stage 1 AKI, but some patients developed

175 fety and efficacy of topical and intradermal gentamicin in 5 RDEB patients with nonsense mutations.

176 There was one very major error (VME) for gentamicin in a Staphylococcus hominis isolate, six VMEs

177 n available to describe the interaction with gentamicin in atomic detail, and neither have any three-

178 However, testing of gentamicin in clinical trials has shown that safe doses

179 lism, we tested the aminoglycosides G418 and gentamicin in hepatoma cell lines (HepG2, Hep3B and Hepa

180 g reformulation to minimizing ototoxicity of gentamicin in patients.

181 verse reactions from a high concentration of gentamicin in the blood.

182 ontrolled compassionate use study of topical gentamicin in which five NPPK patients with c.796C>T wer

183 e reported that, by using a well-established gentamicin-induced hair cell loss model in vitro, adjudi

184 Gentamicin-induced hair cell loss was associated with a

185 m-1 was markedly upregulated in kidney after gentamicin-induced injury and had conserved phagocytic a

186 In this case, treatment with gentamicin induces a population of cells with a strong a

187 ion effects were also observed in an in vivo gentamicin-injured animal model.

188 mutated to alanine and subjected to temporal gentamicin-invasion/gentamicin-survival assay in Chinese

189 Hospital gentamicin is a mixture of five gentamicin C-subtypes an

190 Gentamicin is a potent broad-spectrum aminoglycoside ant

191 Gentamicin is an aminoglycoside widely used in treatment

192 ense-suppression (readthrough) therapy using gentamicin is applicable to NPPK.

193 with aminoglycosides such as streptomycin or gentamicin is effective when initiated early in illness

194 The B1 content of pharmaceutical gentamicin is highly variable and major gentamicins supp

195 Gentamicin is not appropriate as first-line treatment fo

196 that the major components of pharmaceutical gentamicin lack PTC readthrough activity but the minor c

197 Moreover, although gentamicin local treatment alone showed poor efficacy in

198 ing low concentrations of chloramphenicol or gentamicin, lowered MIC towards OTC.

199 aecalis bacteremia, the addition of low-dose gentamicin may decrease the time to bacterial clearance

200 of pain at the injection site was higher for gentamicin (mean visual analogue pain score 36 of 100 in

201 icillin, cefazolin, ciprofloxacin, colistin, gentamicin, meropenem, and tetracycline in comparison to

202 etermining MICs of antibiotics (ceftazidime, gentamicin, meropenem, vancomycin and linezolid), intera

203 ion effects across antibiotics combinations (gentamicin/meropenem or ceftazidime/gentamicin/meropenem

204 nations (gentamicin/meropenem or ceftazidime/gentamicin/meropenem) at different dosages were explored

205 ithin 20 min; in addition, we determined the gentamicin minimum inhibitory concentration (MIC) of the

206 robial activities comparable to the hospital gentamicin mixture.

207 751 prenatal exposures to amikacin (n = 9), gentamicin (n = 345), plazomicin (n = 0), streptomycin (

208 biotics were examined: Ceftazidime (n=2942), Gentamicin (n=4360), Imipenem (n=2235), Ofloxacin (n=311

209 nosa, piperacillin-tazobactam, cefepime, and gentamicin, Neisseria meningitidis and ceftriaxone, and

210 lcitonin gene-related peptide, endothelin-1, gentamicin, norepinephrine and vasopressin.

211 or the most common combination (ampicillin + gentamicin) of 1.96 (95% CrI 1.18, 3.36).

212 xazole , multidrug), or >70% (ciprofloxacin, gentamicin) of total antimicrobial resistance.

213 The topical arm tested 0.1% gentamicin ointment or placebo application 3 times daily

214 form to evaluate the antibacterial effect of gentamicin on E. coli growth.

215 eomic techniques to establish the effects of gentamicin on the proteomes of aerobic and oxygen-limite

216 intramuscular procaine benzylpenicillin and gentamicin once a day for 2 days followed by oral amoxic

217 intramuscular procaine benzylpenicillin and gentamicin once a day for 7 days (reference); oral amoxi

218 al amoxicillin twice daily and intramuscular gentamicin once a day for 7 days; or intramuscular proca

219 The alternative regimens were intramuscular gentamicin once per day and oral amoxicillin twice per d

220 intramuscular procaine benzylpenicillin and gentamicin once per day for 2 days, then oral amoxicilli

221 intramuscular procaine benzylpenicillin and gentamicin once per day for 7 days (group A).

222 either injectable procaine benzylpenicillin-gentamicin once per day or oral amoxicillin treatment tw

223 d to rifaximine, azithromycin, tetracycline, gentamicin or ampicillin.

224 icacy of polypharmacy showed additivity when gentamicin or ceftazidime/gentamicin were combined with

225 rbapenem-sparing regimen of tigecycline plus gentamicin or colistin was effective for treating 24 of

226 other cationic molecules (hNP-1, vancomycin, gentamicin, or calcium-daptomycin).

227 asing microbial susceptibility was observed: gentamicin (P<0.0001), tobramycin (P = 0.005), and imipe

228 dered for plague during pregnancy (amikacin, gentamicin, plazomicin, streptomycin, tobramycin, chlora

229 Prevention (CDC) guidelines recommend 240 mg gentamicin plus 2 g azithromycin for the treatment of go

230 CDC guidelines recommend 240 mg gentamicin plus 2g azithromycin for the treatment of gon

231 We previously demonstrated that gentamicin produced functional type VII collagen in RDEB

232 Invasion was examined by the gentamicin protection assay and fluorescence microscopy.

233 We used a gentamicin protection assay in combination with a chloro

234 ough MDCK and DH82 cells was demonstrated by gentamicin protection assays and three-dimensional immun

235 Bacterial clearance by MDMs was assessed in gentamicin protection assays.

236 recipitation, immunoblot, reporter gene, and gentamicin protection assays.

237 combination of penicillin, streptomycin, and gentamicin (PSG) and then inoculated them with C. albica

238 s who received procaine benzylpenicillin and gentamicin (reference), 76 (10%) of those given amoxicil

239 n-containing cement control; whilst in vitro gentamicin release was increased by 8-fold.

240 We found that the aminoglycosides G418 and gentamicin rescued the expression of the progranulin R49

241 /clindamycin resistance (ermC) (n = 132) and gentamicin resistance (aacA-aphD) (n = 179) genes, none

242 es of E. faecalis and 2 ME, 1 for high-level gentamicin resistance and 1 for nitrofurantoin, in E. fa

243 -resistant Enterococcus (n = 37), high-level gentamicin-resistant Enterococcus (n = 15), linezolid-re

244 Here, we isolated a spontaneous gentamicin-resistant fusA1 mutant (FusA1(P443L)) in whic

245 (Spain), cefepime-resistant E. coli (Spain), gentamicin-resistant Pseudomonas aeruginosa (France) and

246 ctive pressure consistently revealed a small gentamicin-resistant SCV subpopulation that emerged duri

247 With the exception of heme auxotrophs, gentamicin-resistant SCVs displayed greater catalase act

248 dent increase in the population frequency of gentamicin-resistant SCVs.

249 ns and resulted in a significant increase in gentamicin-resistant small colony variant (SCV) formatio

250 3 (4%) patients treated and not treated with gentamicin, respectively (P = .62).

251 ing XP-C cells, treatment with Geneticin and gentamicin resulted in (i) stabilized XPC-mRNA, which wo

252 ce), 76 (10%) of those given amoxicillin and gentamicin (risk difference with reference -1.9, 95% CI

253 s designed to establish a point estimate for gentamicin's efficacy for pharyngeal gonorrhea.

254 ven increases in azithromycin resistance and gentamicin's poor efficacy at the pharynx.

255 ven increases in azithromycin resistance and gentamicin's poor efficacy at the pharynx.

256 edia, including Sabouraud dextrose agar with gentamicin (SDA), inhibitory mold agar (IMA), and brain

257 s that the recommended 2-week treatment with gentamicin seems adequate and preferable in treating non

258 These results suggest that gentamicin should be avoided in orthopedic patients in t

259 The choice between methylprednisolone and gentamicin should be made based on clinical knowledge an

260 erkeratosis was significantly greater on the gentamicin side than the control side (P = 0.0349).

261 patients, hyperkeratosis was improved on the gentamicin side, as determined by a blinded-investigator

262 al arm tested daily intradermal injection of gentamicin solution (8 mg) or placebo into 2 intact skin

263 ned an IncI1 plasmid, encoding resistance to gentamicin, streptomycin and sulfonamides.

264 ore resistant to ciprofloxacin, clindamycin, gentamicin sulfate, and trimethoprim-sulfamethoxazole.

265 GEN is supplied as an aqueous solution of gentamicin sulphate in vials or ampoules and requires he

266 in vivo model of catheter-related infection, gentamicin supplemented with L-arginine led to complete,

267 ical gentamicin is highly variable and major gentamicins suppress the PTC readthrough activity of B1.

268 Topical and intradermal gentamicin suppresses nonsense mutations and induces typ

269 nd subjected to temporal gentamicin-invasion/gentamicin-survival assay in Chinese hamster ovary cells

270 versus 74% [P = 0.02]), lower ampicillin and gentamicin susceptibilities in females aged 18 to 50 yea

271 e study of exposure to a mixed population of Gentamicin-susceptible and resistant Escherichia coli an

272 resistant and resistant to tetracycline and gentamicin than clinical isolates.

273 In contrast, vancomycin and gentamicin, the antibiotics most commonly administered t

274 Intratympanic gentamicin, the standard treatment for refractory Menier

275 Gentamicin therapy may provide a readily available treat

276 ose receiving ampicillin along with low-dose gentamicin therapy.

277 n-inferiority trial comparing treatment with gentamicin to treatment with ceftriaxone for patients wi

278 Ciprofloxacin, gentamicin, tobramycin and vancomycin showed the lowest

279 ion of the HLA class I peptide repertoire of gentamicin-treated cells and identified multiple peptide

280 covered from the colon, spleen, and liver of gentamicin-treated mice than of control mice.

281 teral obstruction (day 7) in mice; and after gentamicin treatment (50 or 200 mg/kg for 10 days) in ra

282 ditis were changed in January 2007, reducing gentamicin treatment in enterococcal infective endocardi

283 The longer duration of gentamicin treatment is associated with worse renal func

284 There were no untoward side effects from gentamicin treatments.

285 nalyses to determine the association between gentamicin use and the number of days alive and free of

286 Short-course empirical gentamicin use in patients with sepsis was associated wi

287 Gentamicin use was associated with higher mortality than

288 The adjusted odds ratios associated with gentamicin use were 1.39 (95% confidence interval [CI],

289 Gentamicin was 60%-80% effective depending on the dose g

290 o enroll 50 evaluable participants; assuming gentamicin was 80% efficacious, the trial would establis

291 ed to enroll 50 evaluable subjects; assuming gentamicin was 80% efficacious, the trial would establis

292 In vitro biofilm tolerance towards gentamicin was assessed using PVC 96 well-plates assays.

293 aminopenicillins, vancomycin and high level gentamicin was moderately associated with income inequal

294 SCV population expansion in the presence of gentamicin was reestablished by selection of phenotype-s

295 igh MICs for moxifloxacin, levofloxacin, and gentamicin were also observed among the Helcococcus stra

296 ed additivity when gentamicin or ceftazidime/gentamicin were combined with meropenem to treat carbape

297 tween HELZJ and the antibiotics amikacin and gentamicin, which resulted in decreased bacterial drug r

298 In the detection of gentamicin with different concentrations of 10-200 mug/m

299 tro planktonic and biofilm susceptibility to gentamicin, with 99% mortality amongst clinically releva

300 at catalyzes methylation of the 6'-carbon of gentamicin X2 (GenX2) to produce G418 during the biosynt